drugset / Trial / NCT06717100
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
NaSingle-groupOpen-labelTreatment
Summary
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
Timeline
- Start
- 2024-12-17
- Primary completion
- 2025-02-17
- Completion
- 2025-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deupirfenidone | Unknown | 825 mg | — |
| Subject | Nintedanib | Small molecule | 150 mg | — |
Indications
No indication recorded.